Investigating the effects of chlordecone exposure on systemic lupus erythematosus in Martinique

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the relationship between exposure to chlordecone, an organochlorine pesticide, and the progression of systemic lupus erythematosus (SLE) among patients in Martinique. It involves collecting blood samples to analyze the concentration of organochlorine pesticides and their potential impact on SLE activity. The study focuses on patients diagnosed with SLE who have been receiving care at the Martinique University Hospital for at least three years. By examining the effects of environmental contaminants on autoimmune diseases, the study seeks to provide insights into the health risks associated with chlordecone exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with systemic lupus erythematosus according to the ACR 1997 or ACR/EULAR 2019 criteria,
* Present in the active line of the internal medicine department of the Martinique University Hospital since 2005,
* Whose illness has been progressing for at least 3 years,
* Living in Martinique or Guadeloupe for at least 1 year,
* Patients who have given their free, informed and written consent.

Exclusion Criteria:

* Patients for whom kidney disease cannot be authenticated or ruled out (refusal, contraindication or impossibility of renal biopsy),
* Patients without social security coverage,
* Current legal protection,
* Patients who have not given their consent to the use of their data,
* Pregnant or breastfeeding women.

Where it's running

• University Hospital Center of Martinique
  Fort-de-France, France Recruiting

Study contacts

• Principal investigator: Benoît SUZON, PhD — University Hospital Center of Martinique
• Study coordinator: Benoît SUZON, PhD
• Email: benoit.suzon@chu-martinique.fr
• Phone: 05 96 55 97 05

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Understanding how ADT for prostate cancer may raise blood pressure and whether nerves or kidneys are involved

  This study tests whether nervous system or kidney dysfunction contributes to high blood pressure in men receiving androgen deprivation therapy for prostate cancer.

  Recruiting Phase 4 Virginia Commonwealth University · Richmond, Virginia · NCT07848828

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.